International investment agreement

HG Semiconductor and GCL Technology Founder Mr. Zhu Gongshan Officially Entered into Shares Subscription and Warrants Subscription Agreement, Mr. Zhu Gongshan has Become Major Strategic Shareholder of the Group

Retrieved on: 
Friday, September 30, 2022
People, Carbon, IDM, Efficiency, CPPCC, National Committee, Intention, EGM, Partnership, Subscription business model, Politics, Semiconductor, Exercise, Technology, International investment agreement, Investment, Solution, Founder, HG, Research, Gallium nitride, Energy storage, Association, Conference, Natural gas, Security (finance), Renewable energy, Mobile phone, Group, Share (finance)

Pursuant to the Investment Agreement, the Group has agreed to issue, and Mr. Zhu has agreed to subscribe for 60 million subscription shares ("Shares Subscription") and 60 million warrants ("Warrants Subscription").

Key Points: 
  • Pursuant to the Investment Agreement, the Group has agreed to issue, and Mr. Zhu has agreed to subscribe for 60 million subscription shares ("Shares Subscription") and 60 million warrants ("Warrants Subscription").
  • Upon completion of the Shares and Warrants Subscription, Mr. Zhu will become the major strategic shareholder of the Group.
  • Pursuant to the Share Subscription Agreement, the 60 million subscription shares represent approximately 10.47% of the existing issued share capital of the Group.
  • After deduction of relevant costs and expenses, the net proceeds from the Shares Subscription are estimated to be approximately HK$180 million.

Marimaca Announces US$15.5 Million Investment from Osisko Gold Royalties

Retrieved on: 
Thursday, September 8, 2022
Mining, International investment agreement, CEO, Legislation, Investment Industry Regulatory Organization of Canada, Exercise, Antofagasta Region, Toronto Stock Exchange, Royalty, Investment, Forward-looking statement, TSX, NSR, GLOBE, Company, Project, Copper, News, Techno-economic assessment, MOD, Osisko Gold Royalties, Holding company

VANCOUVER, British Columbia, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Marimaca Copper Corp. (Marimaca Copper or the Company) (TSX: MARI) is pleased to announce a US$15.5 million investment from Osisko Gold Royalties (Osisko) for a 1.0% Net Smelter Return royalty (the Osisko NSR) (the Investment) on certain claims covering the Marimaca Oxide Deposit (MOD or the Project) and some claims immediately adjacent to it.

Key Points: 
  • VANCOUVER, British Columbia, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Marimaca Copper Corp. (Marimaca Copper or the Company) (TSX: MARI) is pleased to announce a US$15.5 million investment from Osisko Gold Royalties (Osisko) for a 1.0% Net Smelter Return royalty (the Osisko NSR) (the Investment) on certain claims covering the Marimaca Oxide Deposit (MOD or the Project) and some claims immediately adjacent to it.
  • Marimaca has pre-existing rights to retire some of the existing royalties covering the MOD and as such the Investment limits the expected incremental royalty burden on the Project.
  • Under the Investment Agreement, Marimaca has agreed to exercise certain buyback rights in respect of royalties granted under the 1-23 Purchase Agreement and La Atomica option agreement prior to commercial production which total US$6.0 million in aggregate.
  • Neither the Toronto Stock Exchange nor the Investment Industry Regulatory Organization of Canada accepts responsibilityfor the adequacy or accuracy of this release.

Fennec Pharmaceuticals Closes First $5 Million Investment From Petrichor

Retrieved on: 
Monday, August 22, 2022
COVID-19, International investment agreement, Human, Science, Securities Act of 1933, Food and Drug Administration, Germ cell tumor, Drug Quality and Security Act, Cisplatin, U.S. Securities and Exchange Commission, Hepatoblastoma, GLOBE, Company, Risk, Potential, Patient, Medulloblastoma, EMA, Survival, Contagious disease, Sale, Incidence, RESEARCH, Food, SEC, Instability, Bridge bank, FDA, Platinum, CRL, Hearing loss, COG, Cancer, Ototoxicity, FENC, Security (finance), NDA, Sumathi Best Television Current Reporting Award, NASDAQ, Survivor, PDUFA, MAA, Literacy, Investment, Patent, PARK, Disease, Osteosarcoma, STS, Coronavirus, Fennec, OHSU, Health, TSX, Goal, Neuroblastoma, Kool-Aid, Failure, Annual report, Forward-looking statement, Pharmaceutical industry, Nasdaq, Petrichor, Access

RESEARCH TRIANGLE PARK, N.C., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced it has completed the first closing of US$5 million of senior secured promissory notes under our previously announced investment agreement with Petrichor Healthcare Capital Management. Under the terms of the investment agreement, an additional $20 million is to be funded upon the potential U.S. Food and Drug Administration (FDA) approval of PEDMARKTM by September 30, 2022 and satisfaction of other closing conditions. Further, Fennec upon mutual agreement with Petrichor may draw up to $20 million of additional financing under the investment agreement.

Key Points: 
  • Further, Fennec upon mutual agreement with Petrichor may draw up to $20 million of additional financing under the investment agreement.
  • Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development of PEDMARKfor the prevention of platinum-induced ototoxicity in pediatric patients.
  • The Petrichor has completed over 90 investments representing more than$5 billionin invested capital and has held over 30 board seats.
  • If the FDA does not approve the NDA resubmission of PEDMARK, we will not have access to the Petrichor financing.

HG Semiconductor Places 30 Million New Shares and Announces Subscription of 60 Million Shares and 60 Million Warrants by Founder of GCL Technology Mr. Zhu Gongshan

Retrieved on: 
Monday, August 8, 2022
People, Carbon, EGM, Association, Politics, Exercise, Energy storage, CPPCC, Technology, Group, Research, Founder, National Committee, HG, D, International investment agreement, Trust, Natural gas, Gallium nitride, Investment, Solution, Conference, Efficiency, Security (finance), Management

Pursuant to the placing agreement, the Placing Shares represent approximately 5.32% of the existing issued share capital of the Group.

Key Points: 
  • Pursuant to the placing agreement, the Placing Shares represent approximately 5.32% of the existing issued share capital of the Group.
  • After deducting the placing commission and other relevant expenses, the maximum net proceeds will amount to approximately HK$93.6 million.
  • The Group proposes to use the proceeds from the Shares Subscription and Warrants Subscription for the development of GaN business.
  • The subscription shares and warrants shares cannot be sold or transferred for 18 months commencing on the date of issuance.

Fennec Pharmaceuticals Announces Up to $45 Million Investment From Petrichor

Retrieved on: 
Monday, August 1, 2022
Bridge bank, Patient, Sale, OHSU, Food and Drug Administration, Literacy, Incidence, VWAP, Hepatoblastoma, Company, Security (finance), Drug Quality and Security Act, RESEARCH, MAA, Goal, TSX, Investment, Cisplatin, Hearing loss, U.S. Securities and Exchange Commission, Human, Sumathi Best Television Current Reporting Award, EMA, COG, Ototoxicity, Food, PDUFA, Coronavirus, Contagious disease, GLOBE, Potential, STS, SEC, Risk, Securities Act of 1933, Failure, Patent, COVID-19, International investment agreement, CRL, Medulloblastoma, FDA, Survival, Annual report, Science, FENC, Disease, Kool-Aid, Osteosarcoma, Forward-looking statement, Survivor, Neuroblastoma, NDA, Instability, NASDAQ, Cancer, Platinum, PARK, Health, Germ cell tumor, Pharmaceutical industry, Bank, Access, Petrichor, Fennec, Nasdaq

RESEARCH TRIANGLE PARK, N.C., Aug. 01, 2022 (GLOBE NEWSWIRE) --  Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced up to a US$45 million investment from Petrichor Healthcare Capital Management ("Petrichor"). Under the terms of the investment agreement:

Key Points: 
  • Tadd Wessel, Founder and Managing Partner of Petrichor, said, We are pleased to partner with Fennec as they seek to commercialize PEDMARKTM.
  • Our investment strengthens Fennecs balance sheet and provides management with the financial flexibility to potentially capitalize on near-term growth opportunities for PEDMARKTM.
  • Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development of PEDMARKfor the prevention of platinum-induced ototoxicity in pediatric patients.
  • If the FDA does not approve the NDA resubmission of PEDMARK, we will not have access to the Petrichor financing.

NMG Announces the Successful Initial Closing of the Previously Announced Investment Agreement with Mason Graphite

Retrieved on: 
Wednesday, July 20, 2022
Automotive, Other Energy, Mining, Minerals, General Automotive, Energy, Natural Resources, Lac, Sale, TSX Venture Exchange, NMG, 100,000, Joint venture, Legislation, International joint venture, JV, Option, International investment agreement, NYSE, Property, Intention, Risk, Phrase, Risk management, Nature, Mineral, News, Exercise, Mining, SEDAR, Company, NOU, XV, ESG, Proxy, Security (finance), EDGAR

Nouveau Monde Graphite Inc. (NMG or the Company) ( NYSE: NMG , TSXV: NOU ) is pleased to announce the initial closing of the previously announced transactions contemplated under the investment agreement dated May 15, 2022 (the Investment Agreement) between NMG and Mason Graphite Inc. (Mason Graphite) (TSX-V: LLG) (OTCQX: MGPHF), with a view towards the development and operation of Mason Graphites Lac Guret property, based in Qubec, Canada (the Property).

Key Points: 
  • Nouveau Monde Graphite Inc. (NMG or the Company) ( NYSE: NMG , TSXV: NOU ) is pleased to announce the initial closing of the previously announced transactions contemplated under the investment agreement dated May 15, 2022 (the Investment Agreement) between NMG and Mason Graphite Inc. (Mason Graphite) (TSX-V: LLG) (OTCQX: MGPHF), with a view towards the development and operation of Mason Graphites Lac Guret property, based in Qubec, Canada (the Property).
  • Concurrently with the execution of the Option and JV Agreement, NMG and Mason Graphite have completed the private placement of 5.0 million common shares of Mason Graphite (the Initial Shares) to NMG at a price of $0.50 per Initial Share for gross proceeds to Mason Graphite of $2.5 million.
  • Mason Graphite intends to use the net proceeds from the sale of the Initial Shares to fund agreed expenses on the Property pursuant to the Option and JV Agreement.
  • The Initial Shares will be subject to a four-month hold period pursuant to applicable securities laws.

Cresco Labs Announces Voting Results of Its Annual and Special Meeting of Shareholders

Retrieved on: 
Friday, July 15, 2022
Cannabis, Agriculture, Natural Resources, Health, Pharmaceutical, Meeting, Knowledge, Time, SEED, National Energy Education Development Project, Share, Social equity, Cresco Labs, NASDAQ, 2K resolution, Good news, Company, Investment, International investment agreement, New York Stock Exchange, Super, Education, Security (finance), Lorenzo Remedi

The final matter voted on at the Meeting relates to the Companys Super Voting Shares.

Key Points: 
  • The final matter voted on at the Meeting relates to the Companys Super Voting Shares.
  • At the Meeting, the shareholders approved the special resolution (the Special Resolution) to amend the articles of the Company such that following any future listing U.S.
  • Listing Event, no Super Voting Shares will remain outstanding and the Company will be unable to issue new Super Voting Shares.
  • Sunnyside, Cresco Labs national dispensary brand, is a wellness-focused retailer created to build trust, education and convenience for both existing and new cannabis consumers.

Patriot Bank Receives Conditional OCC Approval Required under Merger Agreement with American Challenger

Retrieved on: 
Wednesday, July 6, 2022
Comptroller, Express, CFR, Bank, AS, Tripura Merger Agreement, Attention, Blake Paulson, Bedford Estate, Federal Reserve Board of Governors, Westfield Mall of Scandinavia, GLOBE, Mergers and acquisitions, COVID-19, Failure, Growth, Ownership, U.S. Securities and Exchange Commission, SBA, Telephone, OCC, Risk, Proxy, American Challenge: A Sailing Simulation, International investment agreement, Security (finance), Private Securities Litigation Reform Act, Communication, ANY, Name, Reading, SEC, National Association, Solution, Challenger, American, Patriot

This OCC approval is a requisite regulatory approval under the Merger Agreement.

Key Points: 
  • This OCC approval is a requisite regulatory approval under the Merger Agreement.
  • Michael Carrazza, Patriots Chairman added, The receipt of OCC approval is a significant and necessary milestone that has been achieved toward completing our merger with American Challenger.
  • Patriot is working closely with American Challenger and investors in efforts to meet the remaining closing conditions.
  • Founded in 1994, and now celebrating its 28th year, Patriot National Bancorp, Inc. is the parent holding company of Patriot Bank N.A.

DGAP-News: Successful voluntary public takeover offer by Atlantic BidCo – 60 per cent minimum acceptance level exceeded

Retrieved on: 
Wednesday, May 25, 2022
CEST, Centerbridge Partners, Software, Supervisory board, Investment, Policy, Financial Oversight and Management Board for Puerto Rico, International investment agreement, Advent International, Decision-making, Aareal Bank, Digital Solutions, Proposition, Growth, Atlantic Ocean, Project Panther Bidco, Bidding, Bank, Management

- Chief Executive Officer Jochen Klsges: The required majority of our shareholders decided in favour of a takeover of Aareal Bank by Atlantic BidCo.

Key Points: 
  • - Chief Executive Officer Jochen Klsges: The required majority of our shareholders decided in favour of a takeover of Aareal Bank by Atlantic BidCo.
  • Wiesbaden, 25 May 2022 Atlantic BidCo GmbH (BidCo or the Bidder), a bidder company comprising funds managed and advised by Advent International Corporation (Advent) and Centerbridge Partners (Centerbridge) as well as further entities indirectly holding non-controlling stakes, today announced that the minimum acceptance level of 60 per cent set out in the course of the voluntary public takeover offer was exceeded by the end of the acceptance period on 24 May 2022, 24:00 hours CEST.
  • According to the Bidder, the result of the offer is expected to be announced on 30 May 2022.
  • Jochen Klsges, Chief Executive Officer of Aareal Bank, commented: The required majority of our shareholders decided in favour of a takeover of Aareal Bank by Atlantic BidCo.

DGAP-News: Atlantic BidCo exceeds minimum acceptance threshold

Retrieved on: 
Wednesday, May 25, 2022
Knowledge, Judgement of the German Federal Court of Justice on Google's autocomplete function, DGAP, USD, Canada Pension Plan, Centerbridge Partners, RBS, Twitter, Company, Investment, EUR, Advent International, Tel Aviv Stock Exchange, Facebook, Acquisition, Growth, Finsbury, Software, CPP Investment Board, International investment agreement, Partnership, Time, TEL, THE, LinkedIn, Fund, Atlantic Ocean, Williams & Glyn, Bidding, Senior, INTO, Advent, Federal republic, CPP, Gesellschaft mit beschränkter Haftung, Forward-looking statement, Technology, CET, Person, Physikalisch-Technische Bundesanstalt, News, Security (finance), Bank, Auction, Financial services, Cryptocurrency, Aareal Bank, Nexi, Addiko Bank

The result of the offer at the end of the acceptance period is expected to be announced on 30 May 2022.

Key Points: 
  • The result of the offer at the end of the acceptance period is expected to be announced on 30 May 2022.
  • Ben Langworthy, Senior Managing Director at Centerbridge, added: The shareholders of Atlantic BidCo bring extensive investment experience in European financial services, real estate, software and payments.
  • The additional acceptance period is expected to commence on 31 May 2022 and end at midnight (CET) on 13 June 2022.
  • The transaction is expected to close, subject to regulatory processes, in the fourth quarter of 2022 or the first quarter of 2023.